Eqis Capital Management Inc. reduced its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 4.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 30,102 shares of the biotechnology company’s stock after selling 1,463 shares during the period. Eqis Capital Management Inc. owned 0.16% of Enanta Pharmaceuticals worth $1,409,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in ENTA. Mason Street Advisors LLC increased its stake in Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 212 shares during the last quarter. GAM Holding AG purchased a new position in Enanta Pharmaceuticals in the second quarter valued at approximately $108,000. Municipal Employees Retirement System of Michigan increased its stake in Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 110 shares during the last quarter. SG Americas Securities LLC increased its stake in Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 237 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in Enanta Pharmaceuticals by 62.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,702 shares during the last quarter. Institutional investors own 66.06% of the company’s stock.

ENTA has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. BidaskClub lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. JMP Securities increased their price target on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a research note on Wednesday, October 4th. Royal Bank Of Canada initiated coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating on the stock. Finally, Robert W. Baird increased their price target on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, August 8th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Enanta Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $42.33.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/20/enanta-pharmaceuticals-inc-enta-holdings-reduced-by-eqis-capital-management-inc.html.

Enanta Pharmaceuticals, Inc. (ENTA) traded up 1.22% during midday trading on Friday, hitting $47.98. The stock had a trading volume of 18,975 shares. The company has a 50-day moving average price of $45.49 and a 200-day moving average price of $37.29. Enanta Pharmaceuticals, Inc. has a 12-month low of $22.17 and a 12-month high of $49.50. The company’s market cap is $915.94 million.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative return on equity of 7.74% and a negative net margin of 51.85%. The business had revenue of $7.51 million during the quarter, compared to the consensus estimate of $8.08 million. During the same period in the previous year, the business earned ($0.06) EPS. The business’s quarterly revenue was down 46.3% on a year-over-year basis. Equities analysts anticipate that Enanta Pharmaceuticals, Inc. will post $1.14 EPS for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.